Pre-Filled Syringes West Coast 2021

SMi Group 14 - 15 June 2021, San Diego, USA.
Following the success of the last event, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development, device design, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future.

With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, this year's agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies, case studies on device design and complex formulation, life cycle and control strategies, and innovations in connectivity and digital health.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more. PLUS, two interactive post conference workshops:

Workshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements

Hosted by Shannon Clark, Principal, UserWise, Inc.

Workshop B: Postmarket safety reporting: The current regulatory environment with a global impact

Hosted by Khaudeja Bano, Sr. Medical Director, Abbott Molecular

Featured speakers

  • Brittney Pachucki, Device Engineer, AstraZeneca
  • Darin Zehrung, Global Program Leader, Medical Devices and Health Technologies, PATH
  • Jace Blackburn, Smart Device Engineer, Genentech
  • James P. Wabby, Executive Director, Regulatory Affairs - Device/Combination Products, Allergan
  • Jian Liu, Senior Scientist, Amgen
  • Khaudeja Bano, Senior, Medical Director, Abbott Diagnostics
  • Larry Atupem,  Sr Business Development Specialist, Zeon 
  • Maggie Reiff, Manager, Device Engineering, Pfizer
  • Mark DeStefano, Assoc. Dir. CPD Feasibility, New Technology and Prototyping Development, Teva Pharmaceuticals
  • Natalie Abts, Head of Human Factors Engineering, Genentech
  • Robert Ovadia, Engineer II, Genentech
  • Sarah Mollo, Combination Product Policy Analyst, FDA
  • Severine Duband, Global Category Manager, Nemera
  • Shannon Clark, Principal, UserWise, Inc.
  • Takuya Minezaki, Research Manager, Mitsubishi Gas Chemical Company, Inc.
  • Tina Rees, Associate Director - Human Factors, Ferring Pharmaceuticals
  • Tracy Hsu, Associate Director, Ionis Pharmaceuticals

Key reasons to attend

  • Engage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery
  • Discuss show to optimise current processes to align with global regulatory updates
  • Delve into human factors engineering best practices
  • Uncover how industry is incorporating connectivity and digital health to optimise the user experience

Who should attend

Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers.

Early bird deadlines

  • Register by 31st March to save $200
  • Register by 30th April to save $100

For further information and to register, please visit:
http://www.prefilled-syringes-westcoast.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...